ArticleCancer medicine2025
Serum Pepsinogen as a Biomarker of Gastrointestinal Stromal Tumors (GIST) in Stomach.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Serum Pepsinogen as a Biomarker of Gastrointestinal Stromal Tumors (GIST) in Stomach.Cancer medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundGastric GISTs (GG) are significant mesenchymal tumors. No biomarker has been identified for GG detection. We first observed mucosal atrophy surrounding GG tumors, leading to the hypothesis that localized atrophy may alter serum pepsinogen (PG) levels. Therefore, we developed a machine learning (ML) model incorporating serum PG levels and clinical features to predict GG and differentiate it from gastric cancer (GC).
methodsWe retrospectively analyzed GG and GC patients with tested PG levels before medical intervention. Seven ML algorithms were assessed, and feature importance was determined using SHapley Additive exPlanations (SHAP). Gastric atrophy was assessed histologically using the updated Sydney System.
resultsAfter screening 562 GG and 1090 GC patients, 100 GG and 174 GC samples were included. The multilayer perceptron (MLP) model achieved the highest AUC. The final MLP model, which included 4 features-gender, PGI levels, PGI/PGII ratio, and CEA-predicted GG with an AUC of 0.854. Considering clinical practice and the feature importance identified by the final MLP model, we established a Positive-Gastric-GIST-PG-CEA criterion (PGI < 70 ng/mL, PGI/PGII ratio ≥ 3.0, and CEA ≤ 5 μg/L) referring to the cutoff values revealed by the ROC curve. The Positive-Gastric-GIST-PG-CEA displayed exceptional performance in predicting GG (AUC = 0.772, accuracy = 0.748, specificity = 0.787, sensitivity = 0.680), with performance comparable to the final MLP model (ΔAUC = 0.082, p > 0.05). The contributions of PGI levels, PGI/PGII ratio, and CEA in the Positive-Gastric-GIST-PG-CEA model performance were 0.33, 0.15, and 0.13 based on SHAP analysis. Histopathological evaluation of gastric mucosal atrophy in 50 GG patients revealed peri-tumoral glandular atrophy in 29 cases (58%).
conclusionsThe Positive-Gastric-GIST-PG-CEA criterion is valuable for detecting GG and distinguishing it from GC. Integrating our criteria into existing PG tests could help in GG detection without additional economic expense.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.